JavaScript seems to be disabled in your browser. You must have JavaScript enabled in your browser to utilize the functionality of this website.
Description: Sotagliflozin (formerly also known as LP-80203; LX4211), an antidiabetic agent, is a potent, orally bioavailable, and dual SGLT1/SGLT2 inhibitor with IC50 of 36 nM and 1.8 nM, respectively. Sotagliflozin improves glycemic control in patients with type 2 diabetes in a randomized, placebo-controlled trial. Sotagliflozin also increases serum glucagon-like peptide 1 and peptide YY levels by reducing sodium/glucose cotransporter 1 (SGLT1)-mediated absorption of intestinal glucose.
References: J Pharmacol Exp Ther. 2013 May; 345(2):250-9; Diabetes Metab Syndr Obes. 2015 Feb 26; 8:121-7.
Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.
All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.
Request Data Sheet
Request product datasheet
Request safety datasheet
Compare
Add to wishlist
Get an offer
Request delivery time
Ask a technical question
Submit a bulk request
sales@hoelzel.de
« Back
Subscribe, get 15% off every fifth order and have your items delivered on time!
Forgot Your Password?
Not yet registered? Create account here!